GlassScriptPhysician profile
Rizwan H Khan
NPI 1346390671
$2,691.34
in general payments reported to CMS, 2019-2025
19 companies · $3.50 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $77.60 · 2021: $430 · 2022: $944 · 2023: $276 · 2024: $384 · 2025: $3.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $663.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,892.72 | 2019-2024 | Octrode, Proclaim |
| Relievant Medsystems, INC. | $309.41 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $93.18 | 2020-2021 | |
| Medtronic USA, INC. | $75.17 | 2019 | |
| Collegium Pharmaceutical, INC. | $59.53 | 2019 | |
| Daiichi Sankyo INC. | $35.63 | 2019 | |
| Nevro Corp. | $32.72 | 2024 | Senza |
| Biohaven Pharmaceutical Holding Company LTD. | $23.66 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.01 | 2019 | |
| Medtronic, INC. | $21.01 | 2023 | Synchromedii |
| Boston Scientific Corporation | $17.59 | 2021 | |
| Stryker Corporation | $17.39 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.29 | 2019 | |
| Abbvie INC. | $16.24 | 2022 | |
| Si-Bone, INC. | $14.91 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14.83 | 2019 | |
| Pfizer INC. | $12.87 | 2021 | |
| Orexo US, INC. | $11.68 | 2019 | |
| USA Angelalign Technology Corp | $3.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rizwan Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.